Instil Bio’s hopes for its…
Instil Bio’s hopes for its refreshed clinical pipeline appear to [...]
With the result falling short of…
With the result falling short of the bar Amgen set [...]
Aktis Oncology is aiming to bring…
Aktis Oncology is aiming to bring in $182 million—or more—from [...]
Sanofi has returned to U.S….
Sanofi has returned to U.S. artificial intelligence research biotech Earendil [...]
After five years, Nido Biosciences…
After five years, Nido Biosciences has reached the end of [...]
AbbVie and Gilead each used the…
AbbVie and Gilead each used the holiday season to reward [...]
Johnson & Johnson and Genmab…
Johnson & Johnson and Genmab both used the festive period [...]
Ultragenyx Pharmaceutical has…
Ultragenyx Pharmaceutical has reported the failure of a pair of [...]
As the biopharma wound down for…
As the biopharma wound down for the holidays, the company reported [...]
The festive period brought some…
The festive period brought some unwanted post for both Sanofi [...]